201 related articles for article (PubMed ID: 32582872)
1. Antiretroviral Treatment for HIV Elite Controllers?
Ruiz-Mateos E; Poveda E; Lederman MM
Pathog Immun; 2020; 5(1):121-133. PubMed ID: 32582872
[TBL] [Abstract][Full Text] [Related]
2. Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.
Pernas M; Tarancón-Diez L; Rodríguez-Gallego E; Gómez J; Prado JG; Casado C; Dominguez-Molina B; Olivares I; Coiras M; León A; Rodriguez C; Benito JM; Rallón N; Plana M; Martinez-Madrid O; Dapena M; Iribarren JA; Del Romero J; García F; Alcamí J; Muñoz-Fernández M; Vidal F; Leal M; Lopez-Galindez C; Ruiz-Mateos E
J Virol; 2018 Mar; 92(5):. PubMed ID: 29212942
[TBL] [Abstract][Full Text] [Related]
3. Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication
Jacobs ES; Keating SM; Abdel-Mohsen M; Gibb SL; Heitman JW; Inglis HC; Martin JN; Zhang J; Kaidarova Z; Deng X; Wu S; Anastos K; Crystal H; Villacres MC; Young M; Greenblatt RM; Landay AL; Gange SJ; Deeks SG; Golub ET; Pillai SK; Norris PJ
J Virol; 2017 Mar; 91(6):. PubMed ID: 28053103
[TBL] [Abstract][Full Text] [Related]
4. Evidence for innate immune system activation in HIV type 1-infected elite controllers.
Krishnan S; Wilson EM; Sheikh V; Rupert A; Mendoza D; Yang J; Lempicki R; Migueles SA; Sereti I
J Infect Dis; 2014 Mar; 209(6):931-9. PubMed ID: 24185941
[TBL] [Abstract][Full Text] [Related]
5. Normal T-cell activation in elite controllers with preserved CD4+ T-cell counts.
Bansal A; Sterrett S; Erdmann N; Westfall AO; Dionne-Odom J; Overton ET; Goepfert PA
AIDS; 2015 Nov; 29(17):2245-54. PubMed ID: 26544698
[TBL] [Abstract][Full Text] [Related]
6. Case report: mechanisms of HIV elite control in two African women.
Moosa Y; Tanko RF; Ramsuran V; Singh R; Madzivhandila M; Yende-Zuma N; Abrahams MR; Selhorst P; Gounder K; Moore PL; Williamson C; Abdool Karim SS; Garrett NJ; Burgers WA
BMC Infect Dis; 2018 Jan; 18(1):54. PubMed ID: 29370775
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
Rosás-Umbert M; Llano A; Bellido R; Olvera A; Ruiz-Riol M; Rocafort M; Fernández MA; Cobarsi P; Crespo M; Dorrell L; Del Romero J; Alcami J; Paredes R; Brander C; Mothe B
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487276
[TBL] [Abstract][Full Text] [Related]
8. Plasmatic Levels of IL-18, IP-10, and Activated CD8
Côrtes FH; de Paula HHS; Bello G; Ribeiro-Alves M; de Azevedo SSD; Caetano DG; Teixeira SLM; Hoagland B; Grinsztejn B; Veloso VG; Guimarães ML; Morgado MG
Front Immunol; 2018; 9():1576. PubMed ID: 30050532
[TBL] [Abstract][Full Text] [Related]
9. Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers.
Walker WE; Kurscheid S; Joshi S; Lopez CA; Goh G; Choi M; Barakat L; Francis J; Fisher A; Kozal M; Zapata H; Shaw A; Lifton R; Sutton RE; Fikrig E
J Virol; 2015 May; 89(10):5502-14. PubMed ID: 25740989
[TBL] [Abstract][Full Text] [Related]
10. CD4 T-cell regeneration in HIV-1 elite controllers.
Yang Y; Al-Mozaini M; Buzon MJ; Beamon J; Ferrando-Martinez S; Ruiz-Mateos E; Rosenberg ES; Pereyra F; Yu XG; Lichterfeld M
AIDS; 2012 Mar; 26(6):701-6. PubMed ID: 22301416
[TBL] [Abstract][Full Text] [Related]
11. Proviral Quasispecies Diversity Is Not Associated With Virologic Breakthrough or CD4
de Azevedo SSD; Côrtes FH; Delatorre E; Ribeiro-Alves M; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Bello G
Front Microbiol; 2019; 10():673. PubMed ID: 31001238
[TBL] [Abstract][Full Text] [Related]
12. Current Treatment Options for HIV Elite Controllers: a Review.
Promer K; Karris MY
Curr Treat Options Infect Dis; 2018 Jun; 10(2):302-309. PubMed ID: 30344450
[TBL] [Abstract][Full Text] [Related]
13. Expression profile of host restriction factors in HIV-1 elite controllers.
Abdel-Mohsen M; Raposo RA; Deng X; Li M; Liegler T; Sinclair E; Salama MS; Ghanem Hel-D; Hoh R; Wong JK; David M; Nixon DF; Deeks SG; Pillai SK
Retrovirology; 2013 Oct; 10():106. PubMed ID: 24131498
[TBL] [Abstract][Full Text] [Related]
14. HIV-DNA content in pTfh cells is associated with residual viremia in elite controllers.
García M; Morcilla V; Navarrete-Muñoz MÁ; Fisher K; Cabello A; López-Bernaldo JC; De La Hera F; Barros C; Fernández-Guerrero M; Estrada V; Górgolas M; Benito JM; Palmer S; Rallón N
AIDS; 2021 Mar; 35(3):393-398. PubMed ID: 33252487
[TBL] [Abstract][Full Text] [Related]
15. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.
Julg B; Pereyra F; Buzón MJ; Piechocka-Trocha A; Clark MJ; Baker BM; Lian J; Miura T; Martinez-Picado J; Addo MM; Walker BD
Clin Infect Dis; 2010 Jul; 51(2):233-8. PubMed ID: 20550452
[TBL] [Abstract][Full Text] [Related]
16. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.
Hunt PW; Brenchley J; Sinclair E; McCune JM; Roland M; Page-Shafer K; Hsue P; Emu B; Krone M; Lampiris H; Douek D; Martin JN; Deeks SG
J Infect Dis; 2008 Jan; 197(1):126-33. PubMed ID: 18171295
[TBL] [Abstract][Full Text] [Related]
17. Rapid development of HIV elite control in a patient with acute infection.
Morley D; Lambert JS; Hogan LE; De Gascun C; Redmond N; Rutishauser RL; Thanh C; Gibson EA; Hobbs K; Bakkour S; Busch MP; Farrell J; McGetrick P; Henrich TJ
BMC Infect Dis; 2019 Sep; 19(1):815. PubMed ID: 31533639
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers.
Vigneault F; Woods M; Buzon MJ; Li C; Pereyra F; Crosby SD; Rychert J; Church G; Martinez-Picado J; Rosenberg ES; Telenti A; Yu XG; Lichterfeld M
J Virol; 2011 Mar; 85(6):3015-9. PubMed ID: 21177805
[TBL] [Abstract][Full Text] [Related]
19. Increased biomarkers of cardiovascular risk in HIV-1 viremic controllers and low persistent inflammation in elite controllers and art-suppressed individuals.
Caetano DG; Ribeiro-Alves M; Hottz ED; Vilela LM; Cardoso SW; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Bozza PT; Guimarães ML; Côrtes FH
Sci Rep; 2022 Apr; 12(1):6569. PubMed ID: 35449171
[TBL] [Abstract][Full Text] [Related]
20. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
Omondi FH; Sudderuddin H; Shahid A; Kinloch NN; Jones BR; Miller RL; Tsai O; MacMillan D; Trocha A; Brockman MA; Brumme CJ; Joy JB; Liang R; Walker BD; Brumme ZL
mBio; 2021 Dec; 12(6):e0249021. PubMed ID: 34781741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
